MX2020001406A - Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica. - Google Patents

Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.

Info

Publication number
MX2020001406A
MX2020001406A MX2020001406A MX2020001406A MX2020001406A MX 2020001406 A MX2020001406 A MX 2020001406A MX 2020001406 A MX2020001406 A MX 2020001406A MX 2020001406 A MX2020001406 A MX 2020001406A MX 2020001406 A MX2020001406 A MX 2020001406A
Authority
MX
Mexico
Prior art keywords
mavacamten
treatment
hypertrophic cardiomyopathy
cardiomyopathy
hypertrophic
Prior art date
Application number
MX2020001406A
Other languages
English (en)
Inventor
Evanchik Marc
J Semigran Marc
H Lee June
Lambing Joseph
Green Eric
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of MX2020001406A publication Critical patent/MX2020001406A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan métodos para tratar la cardiomiopatía hipertrófica y la disfunción diastólica.
MX2020001406A 2017-08-04 2018-08-03 Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica. MX2020001406A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762541591P 2017-08-04 2017-08-04
US201762584537P 2017-11-10 2017-11-10
US201862639922P 2018-03-07 2018-03-07
US201862671585P 2018-05-15 2018-05-15
PCT/US2018/045180 WO2019028360A1 (en) 2017-08-04 2018-08-03 MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

Publications (1)

Publication Number Publication Date
MX2020001406A true MX2020001406A (es) 2020-03-09

Family

ID=63350605

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001406A MX2020001406A (es) 2017-08-04 2018-08-03 Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.

Country Status (15)

Country Link
US (3) US20200054636A1 (es)
EP (1) EP3661514A1 (es)
JP (2) JP2020529996A (es)
KR (1) KR20200035973A (es)
CN (1) CN111182901A (es)
AU (2) AU2018311974B2 (es)
CA (1) CA3071948A1 (es)
IL (1) IL272300A (es)
MA (1) MA49760A (es)
MX (1) MX2020001406A (es)
RU (1) RU2020109345A (es)
SG (2) SG11202000549TA (es)
TW (1) TW201916882A (es)
UY (1) UY37834A (es)
WO (1) WO2019028360A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51620A (fr) 2018-01-19 2020-11-25 Cytokinetics Inc Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques
US11964967B2 (en) 2018-06-26 2024-04-23 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020257609A1 (en) * 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
US20230158027A1 (en) * 2019-11-10 2023-05-25 MyoKardia, Inc. Methods of treatment with myosin modulator
EP4097091A1 (en) * 2020-01-28 2022-12-07 Teva Pharmaceuticals International GmbH Solid state forms of mavacamten and process for preparation thereof
KR20230079053A (ko) * 2020-08-28 2023-06-05 미요카디아, 인크. 미오신 조절제를 이용한 치료 방법
AU2021381664A1 (en) 2020-11-20 2023-06-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Triazine dione derivative, preparation method therefor and application thereof in medicine
CA3206864A1 (en) * 2021-02-01 2022-08-04 Divya Jyothi Kallem Process for preparation of mavacamten and solid state forms thereof
CA3209557A1 (en) 2021-03-04 2022-09-09 Bradley P. Morgan Cardiac sarcomere inhibitors
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
CA3225787A1 (en) * 2021-07-16 2023-01-19 Cytokinetics, Inc. Methods for treating hypertrophic cardiomyopathy
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3010910T (lt) * 2013-06-21 2020-03-10 MyoKardia, Inc. Pirimidindiono junginiai, skirti širdies ligoms

Also Published As

Publication number Publication date
RU2020109345A (ru) 2021-09-06
AU2018311974A1 (en) 2020-02-06
US20200054636A1 (en) 2020-02-20
AU2018311974B2 (en) 2024-03-07
US20220226324A1 (en) 2022-07-21
JP2020529996A (ja) 2020-10-15
US20220313695A1 (en) 2022-10-06
SG10202112960QA (en) 2021-12-30
CA3071948A1 (en) 2019-02-07
IL272300A (en) 2020-03-31
MA49760A (fr) 2020-06-10
JP2023065372A (ja) 2023-05-12
SG11202000549TA (en) 2020-02-27
UY37834A (es) 2019-02-28
TW201916882A (zh) 2019-05-01
AU2024203872A1 (en) 2024-06-27
CN111182901A (zh) 2020-05-19
EP3661514A1 (en) 2020-06-10
KR20200035973A (ko) 2020-04-06
WO2019028360A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
MX2020001406A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
PH12020551923A1 (en) Methods and compositions for treating cancer
CA193736S (en) Skin massager
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
MX2017010150A (es) Bacterias probioticas recombinantes.
MX2017011834A (es) Macrociclos peptidomimeticos y usos de los mismos.
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
PH12019501373A1 (en) Methods of treating cochlears synaptopathy
MY190411A (en) Improved uricase sequences and methods of treatment
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
MX2017000306A (es) Metodos para tratar hipotension.
MX2020008195A (es) Compuestos para el tratamiento del dolor.
MX2020003762A (es) Composiciones cosmeticas y metodo para tratar la piel.
IL271728A (en) Materials, uses and treatment methods
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2017013047A (es) Tratamiento de dolor.
ZA202211980B (en) Methods and treatment of trauma
PH12017500275A1 (en) Methods of treating depression using nmda modulators
MX2020003633A (es) Metodo de tratamiento de una lamina de metal y la lamina de metal tratada con este metodo.
PH12016501838A1 (en) Compounds and their methods of use
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
MX2020004058A (es) Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos.
MX2020003587A (es) Metodo de tratamiento de una lamina de metal y la lamina de metal tratada con este metodo.